What is Zacks Research’s Estimate for PCRX FY2024 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Zacks Research lowered their FY2024 EPS estimates for Pacira BioSciences in a report issued on Tuesday, February 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $2.61 for the year, down from their prior estimate of $2.63. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q4 2024 earnings at $0.59 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.68 EPS, Q3 2025 earnings at $0.66 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $2.66 EPS, Q1 2026 earnings at $0.65 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.67 EPS and FY2026 earnings at $2.83 EPS.

Other equities research analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, Barclays dropped their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and an average target price of $22.78.

Pacira BioSciences Trading Down 4.1 %

PCRX opened at $25.44 on Friday. The company’s 50 day moving average is $21.88 and its 200-day moving average is $18.12. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company has a market cap of $1.17 billion, a P/E ratio of -12.53 and a beta of 0.80.

Institutional Trading of Pacira BioSciences

Hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC increased its stake in shares of Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after acquiring an additional 1,208 shares in the last quarter. Caitlin John LLC increased its stake in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares in the last quarter. Finally, Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences during the 3rd quarter worth $98,000. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.